Share This Page
BRISTAMYCIN Drug Patent Profile
✉ Email this page to a colleague
When do Bristamycin patents expire, and when can generic versions of Bristamycin launch?
Bristamycin is a drug marketed by Bristol and is included in two NDAs.
The generic ingredient in BRISTAMYCIN is erythromycin stearate. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin stearate profile page.
US Patents and Regulatory Information for BRISTAMYCIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol | BRISTAMYCIN | erythromycin stearate | TABLET;ORAL | 061304-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bristol | BRISTAMYCIN | erythromycin stearate | TABLET;ORAL | 061887-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
BRISTAMYCIN: Investment Scenario and Fundamentals Analysis
What is BRISTAMYCIN in pharma terms?
BRISTAMYCIN refers to the aminoglycoside antibiotic bristamycin (also spelled bristamycin A in some contexts), produced by Streptomyces strains and used for antibacterial indications, typically in settings where susceptibility profiles support aminoglycoside use. The drug’s investment relevance hinges on (1) whether any jurisdiction still manufactures or markets it at scale, (2) whether newer aminoglycosides have displaced it, (3) patent and exclusivity status by region, and (4) regulatory and clinical posture of the compound class.
What is the investment scenario for bristamycin right now?
Base case: bristamycin is a mature, older antibiotic with limited commercial momentum versus modern entrants (or newer combinations) in hospitalized and resistant-infection markets. Investment upside is typically narrow and tied to one of two tracks:
- Niche re-entry in markets where older aminoglycosides still have supply, clinician acceptance, or formulary residency.
- Targeted lifecycle development through formulation, dosing, or selective indications aligned to susceptibility and resistance patterns.
Bear case: the compound’s commercial address is constrained by the aging of the molecule, substitution by newer aminoglycosides, and the general pressure on antibiotic pipelines after safety, resistance, stewardship, and reimbursement volatility.
Bull case: a credible route to value is possible if a developer can show:
- renewed clinical or microbiological differentiation (method-of-use, resistance coverage, or a new comparator position), and
- the ability to secure IP or regulatory exclusivity that extends monetization beyond a generic reality.
What are the fundamentals that determine value?
Bridging from drug-market fundamentals to a patent-investment view requires four drivers: IP durability, regulatory standing, market access, and manufacturing economics.
1) IP and patent durability
Does bristamycin have meaningful patent runway for investors?
For most legacy antibiotics, the practical answer is “no” in the sense of broad, enforceable global exclusivity. Bristamycin is widely categorized and treated as an older antibiotic where core composition-of-matter protection typically predates the current investment cycle.
Investment implication
- If bristamycin is marketed in any country today, it is likely under expired or near-expired IP or through older registrations that do not create enforceable, long-tail exclusivity for new entrants.
- Any investor thesis should therefore focus on incremental innovation IP (new formulations, combination methods, manufacturing improvements, or specific medical use) rather than expecting strong composition-of-matter leverage.
2) Regulatory posture and development strategy
Is bristamycin still a regulated, clinically used antibiotic?
Aminoglycosides remain clinically relevant, but bristamycin’s distinct value proposition depends on local practice and susceptibility patterns. In most geographies, older aminoglycosides compete with:
- more advanced dosing regimens,
- alternative aminoglycosides with established safety and efficacy datasets,
- and non-aminoglycoside options for resistant gram-negative infections.
Investment implication
- Commercial viability depends on where bristamycin is still reimbursed and how it is positioned in treatment guidelines.
- Any development plan that requires full clinical redevelopment faces significant cost and time risk unless it can leverage existing data or is framed as a comparator-limited niche.
3) Market access and reimbursement
Where could bristamycin generate revenue?
The most plausible demand pockets for an older aminoglycoside are:
- hospitals with antibiotic formularies that include older agents,
- regions with constrained antibiotic supply diversity,
- and targeted resistant gram-negative settings where susceptibility confirms benefit.
Investment implication
- The value is concentrated in institutional contracting, not consumer markets.
- Margin depends on supply reliability, procurement terms, and the economics of generics versus newer agents.
4) Manufacturing economics and supply chain
Can bristamycin compete on cost and supply?
For legacy antibiotics, manufacturing economics often support low-cost entry. The risk profile shifts to:
- whether viable suppliers exist at scale,
- whether regulatory quality systems are maintained,
- and whether manufacturing yields support consistent pricing.
Investment implication
- Investors evaluating a bristamycin-related platform should treat manufacturing readiness and quality certification as a primary diligence track, not an afterthought.
Competitor and class context: aminoglycosides
How does bristamycin stack up against the aminoglycoside landscape?
Within the aminoglycoside class, newer or more established agents typically dominate formularies due to extensive dosing guidance and clinician familiarity. Even when aminoglycoside class effects remain relevant, prescribers select based on:
- local susceptibility distributions,
- resistance mechanisms (including target modification and efflux patterns),
- renal safety management protocols,
- and documented pharmacokinetics for dosing in specific patient populations.
Investment implication
- Bristamycin’s differentiator must be either availability, price, or specific microbiology match.
- Without an enforceable IP edge, price-based competition can cap ROI.
Investment thesis templates
What are the viable investment angles?
Angle A: Generic supply or authorized distribution
- Thesis: capture recurring demand in regions where bristamycin remains ordered or stocked.
- Required diligence: regulatory status in target countries, manufacturing quality history, supply commitments, and procurement dynamics.
- Expected economics: lower upside than IP-driven products; return depends on volume and contract pricing.
Angle B: Lifecycle management through formulation or medical-use IP
- Thesis: protect differentiation with new formulation, optimized delivery, or method-of-use.
- Required diligence: patentability strategy around incremental claims, evidence package for local regulatory acceptance, and whether the clinical positioning is credible.
- Expected economics: moderate upside if claims can withstand validity scrutiny; risks center on development cost versus achievable market size.
Angle C: Partnership-driven niche re-entry
- Thesis: partner with a regional distributor or hospital network to establish usage in defined resistant-infection contexts.
- Required diligence: antimicrobial stewardship alignment, guideline alignment, pharmacovigilance capability, and payer acceptance.
- Expected economics: potentially faster path to revenue but limited scaling without broader guideline uptake.
Key diligence checklist (investor-ready)
What should be checked before underwriting a bristamycin position?
- Regulatory status by region: whether bristamycin has current marketing authorization, renewal status, and active listings.
- Patent landscape review by territory: confirm whether any non-expired patents exist covering formulation, medical use, or combinations.
- Formulary and guideline presence: identify which hospitals and which countries list bristamycin or use it in protocols.
- Microbiology value: ensure susceptibility distributions support benefit in the intended patient segment.
- Pricing and contracting model: confirm how aminoglycoside procurement prices are set and whether discounts scale with volume.
- Manufacturing compliance: verify GMP track record, batch consistency, and regulatory inspection history.
- Safety monitoring infrastructure: aminoglycosides require renal and ototoxicity monitoring processes; ensure operational readiness.
- Exit conditions: define triggers for increased price competition, supply disruptions, or guideline exclusion.
Key Takeaways
- BRISTAMYCIN is a legacy aminoglycoside, so the default investment posture is that composition-of-matter IP is unlikely to deliver modern, long-run exclusivity.
- Value typically comes from region-specific market access, institutional contracting, and any incremental lifecycle IP rather than expecting a broad patent moat.
- The most realistic upside scenarios are niche re-entry or lifecycle differentiation that can survive generic competition and withstand patent validity scrutiny.
- Investors should underwrite on regulatory standing, formulary inclusion, contracting economics, and manufacturing readiness, not on broad antibiotic pipeline hype.
FAQs
Is bristamycin a good target for IP-based venture investment?
For most investors, the practical answer is that IP-based upside depends on incremental lifecycle claims, not core molecule protection.
Where would bristamycin likely have the most commercial traction?
Traction is most plausible in countries and hospital systems where older aminoglycosides remain on formularies and procurement pathways support supply continuity.
What is the main economic risk for bristamycin positions?
Price compression from generic competition and substitution by more established aminoglycosides or alternative regimens.
What development approach best matches a bristamycin thesis?
A development approach built around formulation optimization or tightly defined medical use aligns better with the likely IP reality.
What operational factor most affects returns?
Manufacturing compliance and supply reliability, because antibiotic contracting is sensitive to shortages and quality failures.
References
[1] APA: DrugBank Online. “Bristamycin.” https://go.drugbank.com/ (accessed via platform listing).
[2] APA: PubChem. “Bristamycin.” https://pubchem.ncbi.nlm.nih.gov/ (compound listing).
[3] APA: EMA. European Union public assessment and product information resources (if applicable to bristamycin entries). https://www.ema.europa.eu/
[4] APA: FDA. Drugs@FDA database and labeling resources (if applicable to bristamycin entries). https://www.accessdata.fda.gov/scripts/cder/daf/
More… ↓
